Moneycontrol
HomeNewsBusinessStartupStarting up in times of COVID-19: DigiSparsh sets sights on becoming one lender for all requirements of hospitals and patients
Trending Topics

Starting up in times of COVID-19: DigiSparsh sets sights on becoming one lender for all requirements of hospitals and patients

DigiSparsh has tied up with hospital aggregators to underwrite hospitals and start with invoice discounting and then foray into consumer lending.

July 11, 2020 / 16:04 IST
Story continues below Advertisement
Startups

COVID-19 has been punishing for the Indian startup founders, but the bug of entrepreneurship is not so forgiving either. It is this itch which has forced Saurabh Soni to take the plunge giving up his position as a business head at Happy Loans, a Mumbai-based lending startup to start his own venture in the middle of a pandemic.

Soni has joined hands with Akhilesh Gandhi, a technology professional to start DigiSparsh, a lending startup concentrating on the healthcare space. While lending is a difficult business to be in and COVID-19 has hammered the sector bad, Soni believes healthcare fintech is attractive and is set to grow.

Story continues below Advertisement

Health tech is growing leaps and bounds during the pandemic and going forward consumers will need financial support beyond simple mediclaims and health insurance covers. That is where DigiSparsh intends to build a full scale lending platform for the sector.

Citing a Redseer report, Soni said that the healthcare market in India is around $135 billion in size and out of this around $88 billion is in the private sector.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show